Rocket Lab Narrows 2Q Loss As Revenue Climbs
Dow Jones2026/08/10 20:32By Elias Schisgall
Rocket Lab narrowed its loss and reported rising revenue in the second quarter as its backlog ballooned.
The launch and space systems company on Monday reported a loss of $49.3 million, or 8 cents a share, compared with a loss of $66.4 million, or 13 cents a share, a year earlier.
Revenue grew to $234.1 million, up from $144.5 million a year prior. Product revenues nearly doubled to $181.3 million from $92.7 million, while service revenues ticked up to $52.7 million from $51.8 million.
Analysts polled by FactSet were expecting a loss of 6 cents a share on revenue of $231.6 million. Shares of Rocket Lab fell 1.6% to $78.80 after Monday's bell.
The company ended its quarter with a backlog of $2.36 billion, up 137% year-over-year. So far in the third quarter, the company has entered into new contracts worth more than $1 billion, Chief Executive Officer Peter Beck said.
For the current quarter, the company guided for revenue between $250 million and $265 million. Analysts currently expect $238.5 million in revenue.
Late last month, the company received a $266 million contract for up to 18 suborbital launches for the U.S. Space Force. The first launch is set to take place by the end of the year.
Rocket Lab in June also agreed to acquire Iridium, a satellite operator, for $54 a share in cash and stock, positioning the company to possibly compete with SpaceX's satellite business.
That acquisition, plus the recent purchases of Mynaric and Motiv, "position Rocket Lab to accelerate our future into space applications by becoming a self-launching, tier-1 space power that will deliver critical communications capability to millions of users worldwide," Beck said.
Write to Elias Schisgall at elias.schisgall@wsj.com.
(END) Dow Jones Newswires
August 10, 2026 16:32 ET (20:32 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Outlook Therapeutics Appoints Kevin Lundquist as CFO
Iren Q4 Revenue Falls
VWO ETF Rises 0.6%
VUG ETF Gains 1.7%